U.S. biotech companies are increasingly secretive about their research to protect against rapid imitation by Chinese competitors.
Executives describe a culture of paranoia, using codenames, delaying disclosures to partners, and avoiding public scientific meetings or detailed patents.
This shift reflects growing anxiety over China's rise in biotech innovation and its ability to bring similar drugs to clinical trials quickly.
Geopolitical tensions and IP concerns have pushed American drugmakers to tightly control sensitive data and IP around targets and platforms.
Sources:
US Congress probes big pharma's China trials, pushes FDA data ban
U.S. Biotechs Are Keeping More Secrets to Beat Copycats ...
China's biotech industry is on the rise. Will it reshape US pharma?
US biotech needs government support to match China's gains ...
U.S. Biotechs Are Keeping More Secrets to Beat Copycats ...
U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners
'The bar has risen': China's biotech gains push US ...
China's Burgeoning Biopharmaceutical Competitiveness Demands ...
A Biopharmaceutical Superpower: China's Rise, Its Limits, and What ...
Biopharmaceuticals Rising: China's Strategic Pivot to ...
[PDF] June 29, 2026 Chris Boerner, Ph.D Chairman of the Board and ...